Analysts expect Albireo Pharma, Inc. (NASDAQ:ALBO) to report earnings per share of $3.81 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Albireo Pharma’s earnings. The highest EPS estimate is $4.05 and the lowest is $3.57. Albireo Pharma reported earnings of ($1.06) per share in the same quarter last year, which would indicate a positive year over year growth rate of 459.4%. The business is expected to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Albireo Pharma will report full year earnings of $0.77 per share for the current financial year, with EPS estimates ranging from $0.68 to $0.85. For the next financial year, analysts forecast that the firm will report earnings of ($4.09) per share, with EPS estimates ranging from ($6.08) to ($1.90). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last released its earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.23.
In other news, major shareholder Life Sciences Maste Perceptive bought 275,000 shares of the stock in a transaction on Thursday, January 25th. The shares were acquired at an average cost of $33.00 per share, for a total transaction of $9,075,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $34.44, for a total transaction of $3,444,000.00. The disclosure for this sale can be found here. Corporate insiders own 22.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALBO. Wells Fargo & Company MN lifted its stake in Albireo Pharma by 282.1% in the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 4,688 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Albireo Pharma in the 4th quarter worth approximately $216,000. Artal Group S.A. purchased a new stake in Albireo Pharma in the 4th quarter worth approximately $7,680,000. Sectoral Asset Management Inc lifted its stake in Albireo Pharma by 53.6% in the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after purchasing an additional 84,776 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its stake in Albireo Pharma by 56.2% in the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after purchasing an additional 475,000 shares in the last quarter. Institutional investors and hedge funds own 29.43% of the company’s stock.
ALBO traded down $1.00 during midday trading on Monday, reaching $31.77. The company had a trading volume of 28,079 shares, compared to its average volume of 58,593. The stock has a market cap of $389.87, a price-to-earnings ratio of -10.09 and a beta of 1.61. Albireo Pharma has a 12-month low of $15.31 and a 12-month high of $39.87.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3338880/brokerages-expect-albireo-pharma-inc-albo-to-post-3-81-earnings-per-share.html.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.